

# Clinical trials of Drug eluting stent for coronary artery disease in small vessels

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 drug-eluting stents

| Trial   | Treatments   | Patients   | Trials design and methods                      |
|---|--|--|--|
| <b>paclitaxel eluting stent vs bare-metal stent</b>                                 |  |  |  |
| <b>TAXUS V small vessels sub groups</b><br>n=NA<br>follow-up:                       | paclitaxel-eluting stents<br>versus<br>bare metal stents                     | patients who underwent stent implantation in a single coronary artery stenosis (vessel diameter, 2.25-4.0 mm; lesion length, 10-46 mm), subgroup of small vessel patients  |  |
| <b>sirolimus eluting stent vs bare-metal stent</b>                                  |  |  |  |
| <b>SES-SMART , 2004</b><br>n=129/128<br>follow-up: 8 months                         | Cypher<br>versus<br>Bx Sonic   | Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test   | Parallel groups<br>single-blind<br>Italian     |
| <b>everolimus eluting stent vs paclitaxel eluting stent</b>                         |  |  |  |
| <b>SPIRIT III (small vessel subgroup) , 2009</b><br>n=160/59<br>follow-up: 9 months | 2.5-mm everolimus-eluting stent<br>versus<br>2.5-mm paclitaxel-eluting stent | patients included in SPIRIT III that received at least one 2.5-mm stent  | Parallel groups<br>open                        |
| <b>sirolimus eluting stent vs paclitaxel eluting stent</b>                          |  |  |  |
| <b>ISAR-SMART 3 , 2006</b><br>[NCT00146575]<br>n=180/180<br>follow-up:              | Taxus<br>versus<br>Cypher  | Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMI  | Parallel groups<br>NA<br>Germany               |
| <b>SIRTAX (small vessels subgroup) , 2005</b><br>n=249/246<br>follow-up: 9 months   | Cypher<br>versus<br>Taxus  | Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation | Parallel groups<br>single-blind<br>Switzerland |

## References

### TAXUS V small vessels sub groups, 0:

Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell ME Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23 [16160130]

### SES-SMART, 2004:

Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34 [15585732]

### SPIRIT III (small vessel subgroup), 2009:

Hermiller JB, Fergus T, Pierson W, Su X, Sood P, Sudhir K, Stone GW Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. *Am Heart J* 2009 Dec;158:1005-10 [[19958868](#)] [10.1016/j.ahj.2009.09.018](#)

**ISAR-SMART 3, 2006:**

Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schmig A Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. *Eur Heart J* 2006;27:260-6 [[16401670](#)]

**SIRTAX (small vessels subgroup), 2005:**

Togni M, Eber S, Widmer J, Billinger M, Wenaweser P, Cook S, Vogel R, Seiler C, Eberli FR, Maier W, Corti R, Roffi M, Lscher TF, Garachemani A, Hess OM, Wandel S, Meier B, Jni P, Windecker S Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. *J Am Coll Cardiol* 2007;50:1123-31 [[17868802](#)]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.